After Hours Summary: PANW +5.5%, NTNX +5.5% higher and TECD -19.2%, AMBA -9.3%, COO -1.9% lower following earnings / guidance; APVO surging 114% higher on hyperimmune commercial products sale / ph 1 prelim data newsAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: PANW +5.5%, NTNX +5.5%
Companies trading higher in after hours in reaction to news: APVO +114.3% (Aptevo Therapeutics and MorphoSys end joint development and commercialization agreement for MOR209/ES414; Aptevo regains worldwide rights - preliminary phase I data show markedly lower anti-drug antibody titers; Aptevo also signs agreement for up to $74.5 million to sell hyperimmune commercial products; provides significant non-dilutive funding to execute R&D Strategy), IOVA +16.5% (FDA has granted Fast Track designation for LN-144, the adoptive cell therapy using its TIL technology, for the treatment of advanced melanoma), THC +2.8% (commences Board refreshment process, implements shareholder rights plan to protect NOLs), ETP +1.1% ticking higher; announces FERC approval to put Phase 1A of the Rover Pipeline in service; natural gas service to begin from Cadiz to Defiance August 31), AJRD +0.9% (ticking higher; Aerojet Rocketdyne unit will support Boeing with recently awarded Air Force contract for the Technology Maturation and Risk Reduction phase of the Ground Based Strategic Deterrent acquisition program), GE +0.7% (Charles Gasparino reporting Trian's Nelson Peltz may seek Board seat), NKE +0.6% and UA +0.5% (following LULU results), RGC +0.5% (announces $50 million share repurchase plan)
A few cybersecurity names are higher following Palo Alto Networks (PANW) earnings: FEYE +0.9%, VMW +0.7%, CYBR +0.6%After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: TECD -19.2%, AMBA -9.3%, COO -1.9%, OXM -1.4% (ticking lower)
Companies trading lower in after hours in reaction to news: MGNX -8.5% (announces termination of duvortuxizumab collaboration and license agreement with Janssen), PGNX -4.2% (Progenics Pharm announces study results that show treatment with AZEDRA produced clinically meaningful and durable responses across multiple study endpoints, including radiographic tumor response, tumor biomarker response, and overall survival)